---
alwaysApply: false
description: Complete design specification for Mission Control / Command Center dashboard focused on life-saving capabilities for Ayesha.
---

# Mission Control / Command Center Dashboard - Complete Design Specification

**Last Updated:** January 14, 2025  
**Status:** Design Phase - Ready for Implementation  
**Priority:** P0 - Life-Saving Critical

---

## üéØ EXECUTIVE SUMMARY

**Mission:** Create a unified command center that aggregates ALL existing capabilities into a single, actionable dashboard that directly saves Ayesha's life by enabling rapid, evidence-based decisions.

**Core Value Proposition:** 
- **ONE SCREEN** to see Ayesha's complete genomic profile, treatment options, risks, and next actions
- **REAL-TIME** integration of SAE, Evo2, AlphaFold3, clinical trials, and treatment intelligence
- **ACTIONABLE** - every data point leads to a clear next step
- **LIFE-SAVING** - focused on imminent risks and high-impact interventions

---

## üèóÔ∏è DASHBOARD ARCHITECTURE

### Layout Structure (Responsive Grid)

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  HEADER: AYESHA - STAGE IVB OVARIAN CANCER | OVERALL RISK: HIGH ‚ö†Ô∏è  ‚îÇ
‚îÇ  Critical Alerts: [3] | Last Updated: 2 hours ago                   ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  GENOMIC PROFILE     ‚îÇ  TREATMENT OPTIONS   ‚îÇ  CLINICAL TRIALS     ‚îÇ
‚îÇ  (Evo2 + AlphaFold3) ‚îÇ  (Drug Efficacy)     ‚îÇ  (Personalized)      ‚îÇ
‚îÇ                      ‚îÇ                      ‚îÇ                      ‚îÇ
‚îÇ  ‚Ä¢ Top Drivers       ‚îÇ  ‚Ä¢ PARP Inhibitors   ‚îÇ  ‚Ä¢ Top 5 Matches     ‚îÇ
‚îÇ  ‚Ä¢ DNA Repair Status ‚îÇ  ‚Ä¢ Platinum Agents   ‚îÇ  ‚Ä¢ Eligibility Score ‚îÇ
‚îÇ  ‚Ä¢ Mutation Burden   ‚îÇ  ‚Ä¢ Immunotherapy     ‚îÇ  ‚Ä¢ Success Predict   ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  SAE PREDICTIONS     ‚îÇ  TOXICITY RISKS      ‚îÇ  SUPPORTIVE CARE     ‚îÇ
‚îÇ  (Clinical Outcomes) ‚îÇ  (PGx + Safety)      ‚îÇ  (Food/Supplements)  ‚îÇ
‚îÇ                      ‚îÇ                      ‚îÇ                      ‚îÇ
‚îÇ  ‚Ä¢ Trial Success     ‚îÇ  ‚Ä¢ Drug Interactions ‚îÇ  ‚Ä¢ Vitamin D         ‚îÇ
‚îÇ  ‚Ä¢ Resistance Risk   ‚îÇ  ‚Ä¢ Germline Risks    ‚îÇ  ‚Ä¢ Curcumin          ‚îÇ
‚îÇ  ‚Ä¢ Mechanism Vector  ‚îÇ  ‚Ä¢ Off-Target Safety ‚îÇ  ‚Ä¢ Omega-3           ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¥‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  METASTASIS INTERCEPTION                                            ‚îÇ
‚îÇ  ‚Ä¢ 8-Step Cascade Assessment                                        ‚îÇ
‚îÇ  ‚Ä¢ High-Risk Pathways: [VEGF, MMP9, CXCR4]                         ‚îÇ
‚îÇ  ‚Ä¢ Recommended CRISPR Targets                                       ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò

‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  QUICK ACTIONS                                                      ‚îÇ
‚îÇ  [Analyze New Variant] [Run Treatment Sim] [Design CRISPR]         ‚îÇ
‚îÇ  [Export Report] [Schedule Trial Contact] [Update Profile]         ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

---

## üìä SECTION 1: CRITICAL ALERTS & RISK SCORE (TOP PRIORITY)

### Purpose
**Immediate life-saving information** - what requires action NOW.

### Components

#### 1.1 Overall Risk Score
- **Visual:** Large, color-coded circle (Green/Yellow/Red)
- **Data Source:** Aggregate of metastasis risk, treatment failure probability, resistance prediction
- **Backend Integration:** 
  ```javascript
  GET /api/clinical_genomics/risk_assessment
  {
    overall_risk: 0.78, // 0-1 scale
    risk_level: "HIGH",
    contributing_factors: [
      "HRD-negative (DNA repair intact)",
      "Prior platinum resistance",
      "Stage IVB with ascites"
    ]
  }
  ```

#### 1.2 Critical Alerts Banner
- **Alert Types:**
  - üî¥ **IMMEDIATE:** New high-impact mutation detected (Evo2 delta > threshold)
  - üî¥ **IMMEDIATE:** Predicted treatment resistance (SAE confidence > 0.75)
  - üü† **URGENT:** Drug-drug interaction detected (PGx analysis)
  - üü† **URGENT:** Clinical trial enrollment deadline approaching
  - üü° **MONITOR:** Off-target CRISPR risk above threshold

- **Backend Integration:**
  ```javascript
  GET /api/clinical_genomics/alerts
  {
    alerts: [
      {
        severity: "IMMEDIATE",
        type: "RESISTANCE_PREDICTED",
        message: "SAE predicts 82% probability of platinum resistance",
        action: "Consider alternative therapy or combination",
        timestamp: "2025-01-14T10:30:00Z"
      }
    ]
  }
  ```

#### 1.3 Next Best Action Recommendation
- **Visual:** Large, prominent button with clear text
- **Examples:**
  - "START: PARP Inhibitor (78% predicted success)"
  - "SWITCH: Alternative platinum schedule"
  - "DESIGN: CRISPR intervention for BRCA1"
  - "ENROLL: Clinical trial NCT12345678 (94% match)"

---

## üìä SECTION 2: GENOMIC PROFILE (Evo2 + AlphaFold3)

### Purpose
**Understand what's driving Ayesha's cancer** at the molecular level.

### Components

#### 2.1 Top Driver Mutations
- **Visual:** Sortable table with Evo2 scores
- **Columns:**
  - Gene
  - Mutation (HGVS)
  - Evo2 Delta Score
  - Impact (Functionality, Essentiality, Regulatory)
  - Druggability Status

- **Backend Integration:**
  ```bash
  POST /api/clinical_genomics/analyze_variant
  # Uses existing endpoint from ayesha_plan.mdc (lines 147-158)
  # Returns: spe_score, evidence_tier, badges, insights
  ```

- **Interactive Features:**
  - Click mutation ‚Üí Opens detailed dossier
  - "View AlphaFold3" button ‚Üí Shows structural impact
  - "Design CRISPR" button ‚Üí Pre-populates CRISPR Designer

#### 2.2 DNA Repair Status Card
- **Visual:** Large status indicator
- **Data:**
  - HRD Status: POSITIVE/NEGATIVE/UNCERTAIN
  - DNA Repair Capacity Score (SAE)
  - Implications: "PARP Inhibitor Sensitive" / "Platinum Primary"

- **Backend Integration:**
  ```javascript
  // From SAE feature extraction
  dna_repair_capacity = 0.6 * pathway_ddr + 0.2 * hrr_essentiality + 0.2 * exon_disruption
  ```

#### 2.3 Mutation Burden & Tumor Profile
- **Metrics:**
  - TMB (Tumor Mutational Burden): 8.2 mutations/Mb
  - MSI Status: MSS (Microsatellite Stable)
  - Neoantigen Load: Estimated count
  - PD-L1 Expression: If available

---

## üìä SECTION 3: TREATMENT OPTIONS (Drug Efficacy - S/P/E)

### Purpose
**Show ranked therapy options** with evidence and confidence.

### Components

#### 3.1 Drug Ranking Table
- **Visual:** Interactive table with sparklines for confidence
- **Columns:**
  - Drug Class
  - Efficacy Score (S/P/E)
  - Confidence (0-1)
  - Evidence Tier (I/II/III)
  - Badges (RCT, Guideline, PathwayAligned)
  - SAE Features (line_fitness, cross_resistance)

- **Backend Integration:**
  ```bash
  POST /api/clinical_genomics/analyze_variant
  # Returns drugs array with:
  # - efficacy_score
  # - confidence
  # - evidence_tier
  # - badges
  # - sae_features (if include_sae_features: true)
  ```

- **Example Data:**
  ```javascript
  {
    drug: "Niraparib (PARP Inhibitor)",
    efficacy_score: 0.78,
    confidence: 0.82,
    evidence_tier: "I",
    badges: ["RCT", "PathwayAligned"],
    sae_features: {
      line_fitness: 0.75,
      cross_resistance: 0.15
    },
    rationale: "HRD-positive, no prior PARP exposure"
  }
  ```

#### 3.2 Treatment Line Intelligence
- **Visual:** Timeline showing L1, L2, L3 with current position
- **Data:**
  - Current Line: L3
  - Prior Therapies: Carboplatin, Paclitaxel, Bevacizumab
  - Sequencing Fitness: Scores for potential next therapies
  - Cross-Resistance Warnings

#### 3.3 Resistance Prediction
- **Visual:** Warning card if resistance detected
- **Data:**
  - Predicted Resistance Mechanisms (from SAE)
  - Confidence Score
  - Alternative Strategies
  - Time to Resistance (estimated)

---

## üìä SECTION 4: SAE CLINICAL OUTCOME PREDICTIONS

### Purpose
**Predict clinical trial success** and treatment outcomes.

### Components

#### 4.1 Clinical Trial Success Predictor
- **Visual:** Probability gauge for each trial type
- **Data:**
  - PARP Inhibitor Trial: 78% predicted success
  - Platinum Combination: 62% predicted success
  - Immunotherapy: 34% predicted success

- **Backend Integration:**
  ```javascript
  // From SAE validation work
  GET /api/sae/predict_trial_success
  {
    patient_profile: {
      dna_repair_capacity: 0.45,
      mechanism_vector: [0.9, 0.2, 0.3, 0.6, 0.1, 0.4, 0.2], // DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux
      platinum_response: "sensitive"
    },
    predictions: [
      {
        trial_type: "PARP_INHIBITOR",
        success_probability: 0.78,
        confidence: 0.82,
        rationale: "High DDR pathway activity, HRD-positive"
      }
    ]
  }
  ```

#### 4.2 Mechanism Vector Visualization
- **Visual:** 7-pathway radar chart
- **Pathways:** DDR, MAPK, PI3K, VEGF, HER2, IO, Efflux
- **Interactive:** Click pathway ‚Üí See contributing genes/mutations

#### 4.3 Resistance Risk Timeline
- **Visual:** Timeline showing predicted resistance emergence
- **Data:**
  - Current Therapy: Platinum + Bevacizumab
  - Predicted Resistance: 6-9 months (confidence 0.68)
  - Mechanism: VEGF pathway escape
  - Recommended Action: Add anti-VEGF or switch to PARP

---

## üìä SECTION 5: CLINICAL TRIALS (Personalized Matching)

### Purpose
**Show most relevant trials** with eligibility and predicted success.

### Components

#### 5.1 Top Trial Matches
- **Visual:** Card-based layout (5 trials max)
- **Data per Trial:**
  - Trial ID (NCT number)
  - Title
  - Phase
  - Location (proximity to Ayesha)
  - Eligibility Match Score (0-100%)
  - SAE-Predicted Success Rate
  - Quick Action: "Schedule Contact"

- **Backend Integration:**
  ```bash
  GET /api/clinical_trials/search
  # With filters: disease, biomarkers, location
  # Returns: matched trials with eligibility scores
  ```

#### 5.2 Eligibility Criteria Breakdown
- **Visual:** Expandable section per trial
- **Data:**
  - ‚úÖ Met: HRD-positive, Stage IV, ECOG 0-1
  - ‚ö†Ô∏è Conditional: Prior platinum (allowed if >6 months)
  - ‚ùå Not Met: None

---

## üìä SECTION 6: TOXICITY RISKS (PGx + Safety)

### Purpose
**Prevent life-threatening adverse events** before they happen.

### Components

#### 6.1 Pharmacogenomic Warnings
- **Visual:** Red/yellow alert cards
- **Data:**
  - Germline Variants Detected: DPYD (c.1905+1G>A)
  - Drug Impact: 5-FU ‚Üí Severe toxicity risk
  - Recommendation: Avoid or reduce dose by 50%

- **Backend Integration:**
  ```bash
  POST /api/safety/toxicity_risk
  # From ayesha_plan.mdc (lines 254-263)
  {
    patient: {
      germlineVariants: [
        {gene: "DPYD", chrom: "1", pos: 97450058, ref: "C", alt: "T"}
      ]
    },
    candidate: {
      type: "drug",
      moa: "platinum_agent"
    }
  }
  ```

#### 6.2 Drug-Drug Interactions
- **Visual:** Interaction matrix
- **Data:**
  - Current Medications: Warfarin, Metformin
  - Proposed Therapy: Niraparib
  - Interaction Level: MODERATE
  - Management: Monitor INR weekly

#### 6.3 Off-Target CRISPR Risk
- **Visual:** Safety score gauge
- **Data:**
  - Guide RNA Sequence
  - Predicted Off-Targets: 3 (1mm), 12 (2mm)
  - Safety Score: 0.87
  - Recommendation: APPROVED for design

- **Backend Integration:**
  ```bash
  POST /api/safety/off_target_preview
  # From ayesha_plan.mdc (lines 265-272)
  ```

---

## üìä SECTION 7: SUPPORTIVE CARE (Food/Supplements)

### Purpose
**Evidence-based recommendations** for complementary interventions.

### Components

#### 7.1 Recommended Supplements
- **Visual:** Card layout with S/P/E scores
- **Data per Supplement:**
  - Name: Vitamin D
  - S/P/E Score: 0.68
  - Evidence Tier: II
  - Rationale: "Supports immune function, anti-inflammatory"
  - Dosage: 2000-4000 IU/day
  - Interactions: None with current meds
  - Safety: GREEN

- **Backend Integration:**
  ```bash
  POST /api/hypothesis/validate_food_dynamic
  # From ayesha_plan.mdc (lines 194-214)
  {
    compound: "Vitamin D",
    disease_context: {
      disease: "ovarian_cancer_hgs",
      biomarkers: {HRD: "POSITIVE", TMB: 8.2},
      pathways_disrupted: ["DNA repair", "Cell cycle"]
    },
    treatment_history: {
      current_line: "L3",
      prior_therapies: ["carboplatin", "paclitaxel"]
    }
  }
  ```

#### 7.2 Lifestyle Recommendations
- **Data:**
  - Exercise: Moderate intensity, 150 min/week
  - Diet: Mediterranean, anti-inflammatory
  - Sleep: 7-9 hours/night
  - Stress Management: Mindfulness, therapy

---

## üìä SECTION 8: METASTASIS INTERCEPTION

### Purpose
**Prevent cancer spread** through targeted interventions.

### Components

#### 8.1 8-Step Cascade Assessment
- **Visual:** Horizontal progress bar with risk scores per step
- **Steps:**
  1. Local Invasion (RISK: HIGH - 0.82)
  2. Intravasation (RISK: MODERATE - 0.65)
  3. Circulation Survival (RISK: HIGH - 0.78)
  4. Extravasation (RISK: MODERATE - 0.58)
  5. Dormancy (RISK: LOW - 0.32)
  6. Angiogenesis (RISK: HIGH - 0.89)
  7. Immune Evasion (RISK: MODERATE - 0.61)
  8. Colonization (RISK: HIGH - 0.75)

- **Backend Integration:**
  ```bash
  POST /api/metastasis/assess
  # From metastasis framework completion
  # Returns: risk_scores per step, contributing genes
  ```

#### 8.2 High-Risk Pathways
- **Visual:** Highlighted pathway cards
- **Data:**
  - VEGF Pathway: HIGH (0.89) ‚Üí Drives angiogenesis
  - MMP9 Activity: HIGH (0.82) ‚Üí ECM degradation
  - CXCR4/CXCL12: HIGH (0.78) ‚Üí Homing to metastatic sites

#### 8.3 CRISPR Target Recommendations
- **Visual:** Ranked list of targets
- **Data:**
  - Target: VEGFA
  - Rationale: Block angiogenesis (Step 6)
  - Feasibility Score: 0.91
  - Safety Score: 0.87
  - Action: [Design Guides] button

---

## üìä SECTION 9: QUICK ACTIONS (Bottom Bar)

### Purpose
**One-click access** to critical functions.

### Components

#### 9.1 Action Buttons
- **[Analyze New Variant]**
  - Opens: Mutation input form
  - Runs: Evo2 scoring + AlphaFold3 + S/P/E
  - Updates: All dashboard sections

- **[Run Treatment Simulation]**
  - Opens: Treatment scenario builder
  - Compares: Multiple therapy sequences
  - Predicts: Outcomes using SAE

- **[Design CRISPR Intervention]**
  - Opens: CRISPR Designer
  - Pre-populates: High-priority targets from metastasis section
  - Runs: Safety checks automatically

- **[Export Clinical Report]**
  - Generates: PDF with all dashboard data
  - Includes: Genomic profile, treatment recommendations, trial matches
  - Action: Download or send to oncologist

- **[Schedule Trial Contact]**
  - Opens: Trial coordinator contact form
  - Pre-fills: Ayesha's eligibility data
  - Sends: Email to trial site with attached report

- **[Update Patient Profile]**
  - Opens: Profile editor
  - Updates: Biomarkers, treatment history, medications
  - Refreshes: All predictions automatically

---

## üîå TECHNICAL IMPLEMENTATION

### Frontend Architecture

#### Component Structure
```
src/pages/MissionControl/
‚îú‚îÄ‚îÄ MissionControlDashboard.jsx (Main container)
‚îú‚îÄ‚îÄ components/
‚îÇ   ‚îú‚îÄ‚îÄ CriticalAlerts.jsx
‚îÇ   ‚îú‚îÄ‚îÄ RiskScore.jsx
‚îÇ   ‚îú‚îÄ‚îÄ GenomicProfile/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ DriverMutations.jsx
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ DNARepairStatus.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ MutationBurden.jsx
‚îÇ   ‚îú‚îÄ‚îÄ TreatmentOptions/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ DrugRanking.jsx
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ TreatmentTimeline.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ ResistancePrediction.jsx
‚îÇ   ‚îú‚îÄ‚îÄ SAEPredictions/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ TrialSuccessPredictor.jsx
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ MechanismVector.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ ResistanceTimeline.jsx
‚îÇ   ‚îú‚îÄ‚îÄ ClinicalTrials/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ TrialMatches.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ EligibilityCriteria.jsx
‚îÇ   ‚îú‚îÄ‚îÄ ToxicityRisks/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ PharmacogenomicWarnings.jsx
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ DrugInteractions.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ OffTargetRisk.jsx
‚îÇ   ‚îú‚îÄ‚îÄ SupportiveCare/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ SupplementRecommendations.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ LifestyleGuidance.jsx
‚îÇ   ‚îú‚îÄ‚îÄ MetastasisInterception/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ CascadeAssessment.jsx
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ HighRiskPathways.jsx
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ CRISPRTargets.jsx
‚îÇ   ‚îî‚îÄ‚îÄ QuickActions.jsx
‚îî‚îÄ‚îÄ hooks/
    ‚îú‚îÄ‚îÄ useMissionControlData.js
    ‚îú‚îÄ‚îÄ useRiskAssessment.js
    ‚îú‚îÄ‚îÄ useTreatmentOptions.js
    ‚îî‚îÄ‚îÄ useRealTimeUpdates.js
```

#### Data Fetching Strategy
```javascript
// useMissionControlData.js
import { useEffect, useState } from 'react';

export const useMissionControlData = (patientId) => {
  const [data, setData] = useState({
    riskAssessment: null,
    genomicProfile: null,
    treatmentOptions: null,
    saePredict: null,
    clinicalTrials: null,
    toxicityRisks: null,
    supportiveCare: null,
    metastasisRisk: null,
    loading: true,
    error: null
  });

  useEffect(() => {
    const fetchAllData = async () => {
      try {
        // Parallel API calls for all sections
        const [
          riskAssessment,
          genomicProfile,
          treatmentOptions,
          saePredict,
          clinicalTrials,
          toxicityRisks,
          supportiveCare,
          metastasisRisk
        ] = await Promise.all([
          fetch(`/api/clinical_genomics/risk_assessment?patient_id=${patientId}`),
          fetch(`/api/clinical_genomics/analyze_variant`, {
            method: 'POST',
            body: JSON.stringify({
              mutations: data.mutations,
              disease: 'ovarian_carcinoma',
              profile: 'richer',
              options: { include_sae_features: true }
            })
          }),
          // ... other API calls
        ]);

        setData({
          riskAssessment: await riskAssessment.json(),
          genomicProfile: await genomicProfile.json(),
          // ... other data
          loading: false,
          error: null
        });
      } catch (error) {
        setData(prev => ({ ...prev, loading: false, error: error.message }));
      }
    };

    fetchAllData();
  }, [patientId]);

  return data;
};
```

#### Real-Time Updates
```javascript
// useRealTimeUpdates.js
import { useEffect, useState } from 'react';

export const useRealTimeUpdates = (patientId) => {
  const [updates, setUpdates] = useState([]);

  useEffect(() => {
    // WebSocket connection for real-time alerts
    const ws = new WebSocket(`ws://localhost:8000/api/ws/alerts/${patientId}`);

    ws.onmessage = (event) => {
      const alert = JSON.parse(event.data);
      setUpdates(prev => [alert, ...prev]);
    };

    return () => ws.close();
  }, [patientId]);

  return updates;
};
```

### Backend Endpoints

#### New Endpoints Required

##### Risk Assessment Aggregator
```python
# api/routers/clinical_genomics.py

@router.get("/risk_assessment")
async def get_risk_assessment(patient_id: str):
    """
    Aggregate risk score from multiple sources.
    """
    # Get metastasis risk
    metastasis_risk = await metastasis_service.assess_risk(patient_id)
    
    # Get treatment failure probability
    treatment_risk = await treatment_service.predict_failure(patient_id)
    
    # Get resistance prediction
    resistance_risk = await sae_service.predict_resistance(patient_id)
    
    overall_risk = (
        metastasis_risk * 0.4 +
        treatment_risk * 0.3 +
        resistance_risk * 0.3
    )
    
    return {
        "overall_risk": overall_risk,
        "risk_level": "HIGH" if overall_risk > 0.7 else "MODERATE" if overall_risk > 0.4 else "LOW",
        "contributing_factors": [...]
    }
```

##### SAE Trial Success Predictor
```python
# api/routers/sae.py

@router.post("/predict_trial_success")
async def predict_trial_success(patient_profile: PatientProfile):
    """
    Predict clinical trial success based on SAE features.
    """
    # Extract SAE features
    dna_repair = compute_dna_repair_capacity(patient_profile)
    mechanism_vector = compute_mechanism_vector(patient_profile)
    
    # Run predictions for different trial types
    predictions = []
    for trial_type in ["PARP_INHIBITOR", "PLATINUM_COMBO", "IMMUNOTHERAPY"]:
        success_prob = sae_model.predict(
            dna_repair=dna_repair,
            mechanism_vector=mechanism_vector,
            trial_type=trial_type
        )
        
        predictions.append({
            "trial_type": trial_type,
            "success_probability": success_prob,
            "confidence": sae_model.confidence,
            "rationale": sae_model.explain()
        })
    
    return {"predictions": predictions}
```

##### Critical Alerts Service
```python
# api/routers/clinical_genomics.py

@router.get("/alerts")
async def get_critical_alerts(patient_id: str):
    """
    Generate critical alerts based on latest patient data.
    """
    alerts = []
    
    # Check for new high-impact mutations
    new_mutations = await check_new_mutations(patient_id)
    for mut in new_mutations:
        if mut.evo2_delta > 5.0:  # High impact threshold
            alerts.append({
                "severity": "IMMEDIATE",
                "type": "HIGH_IMPACT_MUTATION",
                "message": f"New {mut.gene} mutation detected with Evo2 delta {mut.evo2_delta}",
                "action": "Review genomic profile and consider therapeutic implications",
                "timestamp": datetime.now().isoformat()
            })
    
    # Check for resistance prediction
    resistance_pred = await sae_service.predict_resistance(patient_id)
    if resistance_pred.probability > 0.75:
        alerts.append({
            "severity": "IMMEDIATE",
            "type": "RESISTANCE_PREDICTED",
            "message": f"SAE predicts {resistance_pred.probability*100}% probability of resistance",
            "action": "Consider alternative therapy or combination",
            "timestamp": datetime.now().isoformat()
        })
    
    # Check for drug interactions
    interactions = await toxicity_service.check_interactions(patient_id)
    for interaction in interactions:
        if interaction.severity == "SEVERE":
            alerts.append({
                "severity": "URGENT",
                "type": "DRUG_INTERACTION",
                "message": f"{interaction.drug1} + {interaction.drug2}: {interaction.effect}",
                "action": interaction.recommendation,
                "timestamp": datetime.now().isoformat()
            })
    
    return {"alerts": sorted(alerts, key=lambda x: x["severity"], reverse=True)}
```

---

## üé® UI/UX DESIGN PRINCIPLES

### Visual Design

#### Color Coding for Severity
- üî¥ **RED:** Immediate action required (life-threatening)
- üü† **ORANGE:** Urgent action required (within 24-48 hours)
- üü° **YELLOW:** Monitor closely (within 1 week)
- üü¢ **GREEN:** On track, no immediate concerns
- ‚ö™ **GRAY:** Pending data or not applicable

#### Typography Hierarchy
- **Risk Score:** 48px, bold, color-coded
- **Section Headers:** 24px, bold
- **Card Titles:** 18px, semi-bold
- **Body Text:** 14px, regular
- **Captions:** 12px, light

#### Interactive Elements
- **Hover States:** Subtle elevation + border highlight
- **Click Actions:** Ripple effect + loading indicator
- **Expandable Sections:** Smooth accordion animation
- **Tooltips:** Context-sensitive help on all medical terms

### Responsive Design
- **Desktop (>1200px):** 3-column grid layout
- **Tablet (768-1200px):** 2-column grid layout
- **Mobile (<768px):** Single column, collapsible sections

### Accessibility
- **WCAG 2.1 AA Compliance:** All text contrast ratios ‚â•4.5:1
- **Keyboard Navigation:** Full keyboard support for all actions
- **Screen Reader Support:** Proper ARIA labels on all components
- **Focus Indicators:** Clear visual focus states

---

## üì± USER WORKFLOWS

### Workflow 1: Morning Dashboard Review (5 minutes)
1. **Login** ‚Üí Dashboard loads with latest data
2. **Check Critical Alerts** ‚Üí 3 alerts: resistance predicted, trial enrollment deadline, new mutation
3. **Review Risk Score** ‚Üí Overall: HIGH (0.78), up from 0.72 last week
4. **Scan Treatment Options** ‚Üí PARP inhibitor still top-ranked (0.78 efficacy)
5. **Check SAE Predictions** ‚Üí 78% trial success for PARP, 6-9 months to resistance
6. **Review Quick Actions** ‚Üí Schedule trial contact for NCT12345678
7. **Export Report** ‚Üí Generate PDF for oncologist appointment

### Workflow 2: New Mutation Detected (10 minutes)
1. **Alert Received** ‚Üí Push notification: "New high-impact mutation detected"
2. **Navigate to Dashboard** ‚Üí Red banner: "BRCA2 c.5946delT detected"
3. **Click Alert** ‚Üí Opens Genomic Profile section
4. **Review Mutation Details** ‚Üí Evo2 delta: 8.2, Impact: Frameshift, Pathogenic
5. **Check Treatment Impact** ‚Üí PARP efficacy increased from 0.78 ‚Üí 0.89
6. **Review SAE Update** ‚Üí Trial success probability increased from 78% ‚Üí 91%
7. **Update Clinical Trials** ‚Üí New trial matches appear (BRCA2-specific)
8. **Export Updated Report** ‚Üí Send to oncologist with treatment recommendations

### Workflow 3: Pre-Treatment Planning (30 minutes)
1. **Open Dashboard** ‚Üí Review complete patient profile
2. **Navigate to Treatment Options** ‚Üí Compare PARP vs Platinum
3. **Run Treatment Simulation** ‚Üí Compare outcomes for different sequences
4. **Check Toxicity Risks** ‚Üí No PGx warnings for PARP
5. **Review Clinical Trials** ‚Üí 5 matches, 2 near location
6. **Check Metastasis Risk** ‚Üí High risk in angiogenesis (Step 6)
7. **Explore CRISPR Options** ‚Üí VEGFA target recommended
8. **Design CRISPR Guides** ‚Üí 5 guides generated, safety scores 0.87-0.92
9. **Export Comprehensive Report** ‚Üí Include genomic profile, treatment options, CRISPR designs
10. **Schedule Trial Contacts** ‚Üí Send report to 2 trial coordinators

---

## üöÄ IMPLEMENTATION ROADMAP

### Phase 1: Core Infrastructure (Week 1)
- [ ] Set up dashboard container component
- [ ] Implement data fetching hooks
- [ ] Create basic grid layout
- [ ] Add loading and error states

### Phase 2: Critical Sections (Week 2)
- [ ] Critical Alerts & Risk Score
- [ ] Genomic Profile (Evo2 integration)
- [ ] Treatment Options (S/P/E integration)
- [ ] Quick Actions bar

### Phase 3: Advanced Features (Week 3)
- [ ] SAE Predictions
- [ ] Clinical Trials matching
- [ ] Toxicity Risks (PGx integration)
- [ ] Metastasis Interception

### Phase 4: Supporting Features (Week 4)
- [ ] Supportive Care recommendations
- [ ] Real-time updates (WebSocket)
- [ ] Export functionality
- [ ] User preferences

### Phase 5: Polish & Testing (Week 5)
- [ ] UI/UX refinements
- [ ] Performance optimization
- [ ] Accessibility testing
- [ ] User acceptance testing

---

## üéØ SUCCESS METRICS

### Quantitative Metrics
- **Page Load Time:** <2 seconds for full dashboard
- **API Response Time:** <500ms for all backend calls
- **Real-Time Alert Latency:** <1 second from detection to display
- **Export Generation Time:** <5 seconds for PDF report

### Qualitative Metrics
- **User Satisfaction:** >90% find dashboard useful
- **Decision Speed:** 50% reduction in time to treatment decision
- **Alert Accuracy:** >85% of critical alerts lead to meaningful action
- **Information Overload:** <10% of users report feeling overwhelmed

### Clinical Impact Metrics
- **Treatment Selection Confidence:** >80% of oncologists feel more confident
- **Adverse Event Prevention:** >70% reduction in preventable toxicities
- **Trial Enrollment:** 50% increase in eligible trial enrollments
- **Time to Intervention:** 40% reduction in time from mutation detection to action

---

## üìù NOTES & CONSIDERATIONS

### Data Privacy & Security
- All patient data encrypted at rest and in transit
- HIPAA-compliant data handling
- Audit logs for all data access
- User authentication and authorization

### Regulatory Compliance
- Clear "Research Use Only" disclaimers
- No diagnostic claims
- Proper attribution for all data sources
- Version tracking for all predictions

### Scalability
- Modular architecture for easy feature additions
- Caching strategy for frequently accessed data
- Asynchronous data fetching to prevent blocking
- Progressive loading for better perceived performance

### Future Enhancements
- **AI Co-Pilot Chat:** Conversational interface for queries
- **Predictive Timeline:** Visualize expected disease progression
- **Multi-Patient View:** Compare across patient cohort
- **Mobile App:** Native iOS/Android apps
- **Telemedicine Integration:** Video consultations within dashboard
- **Electronic Health Record (EHR) Integration:** Bi-directional data sync

---

## üé¨ CONCLUSION

This Mission Control dashboard represents a **paradigm shift** in precision oncology. By aggregating all our existing capabilities (Evo2, AlphaFold3, SAE, S/P/E orchestration, clinical trials, toxicity risks, metastasis interception) into a single, actionable interface, we can:

1. **Save Lives:** Immediate visibility into critical risks and recommended interventions
2. **Accelerate Decisions:** Reduce time from data to action by 50%+
3. **Improve Outcomes:** Evidence-based treatment selection with >80% confidence
4. **Empower Patients:** Clear understanding of their genomic profile and options
5. **Enable Research:** Platform for continuous learning and improvement

**This dashboard is not just a UI - it's a life-saving command center for Ayesha and patients like her.**

---

**Next Steps:**
1. Review this design specification with the team
2. Prioritize features based on clinical impact
3. Begin Phase 1 implementation (Core Infrastructure)
4. Iterate based on user feedback from oncologists and patients

**Status:** READY FOR IMPLEMENTATION ‚öîÔ∏è
